A STATISTICAL MODEL TO STUDY COST-EFFECTIVENESS OF ANTIVIRAL TREATMENT IN HCV RECURRENCE AFTER LIVER TRANSPLANTATION

被引：0
|
作者：
Logge, Christoph [1 ]
Vettorazzi, Eik [2 ]
Fischer, Lutz [1 ]
Nashan, Bjoern [1 ]
Sterneck, Martina [1 ]
机构：
[1] Med Univ Ctr Hamburg Eppendorf, Dept Hepatobiliary & Transplant Surg, Hamburg, Germany
[2] Med Univ Ctr Hamburg Eppendorf, Dept Med Biometry & Epidemiol, Hamburg, Germany
来源：
HEPATOLOGY | 2009年 / 50卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
519
引用
收藏
页码：553A / 553A
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness in liver transplantation a systematic review.
    van der Hilst, Christian S.
    Ijtsma, Alexander J. C.
    Nijkamp, Danielle M.
    Bottema, Jan T.
    Slooff, Maarten J. H.
    TenVergert, Elisabeth M.
    LIVER TRANSPLANTATION, 2007, 13 (06) : S198 - S198
  • [42] Cost-effectiveness of decontamination of the digestive tract in liver transplantation
    van Enckevort, PJ
    Zwaveling, JH
    Bottema, JT
    Maring, JK
    Klompmaker, IJ
    Slooff, MJH
    TenVergert, EM
    TRANSPLANTATION, 1999, 67 (07) : S188 - S188
  • [43] Cost-effectiveness of liver transplantation in methylmalonic and propionic acidemias
    Li, Meng
    Dick, Andre
    Montenovo, Martin
    Horslen, Simon
    Hansen, Ryan
    LIVER TRANSPLANTATION, 2015, 21 (09) : 1208 - 1218
  • [44] Treatment of HCV-recurrence after liver transplantation with sofosbuvir/ledipasvir: the role of ribavirin
    Eurich, Dennis
    Globke, Brigitta
    Nathanael, Raschzok
    Teegen, Eva
    Dimrah, Iman
    Schott, Eckart
    Pratschke, Johann
    TRANSPLANTATION, 2016, 100 (07) : S274 - S274
  • [45] HCV recurrence after liver transplantation (OLT):: Open treatment with natural α-IFN.
    Fagiuoli, S
    Tarehetta, S
    Burra, P
    Boccagni, P
    Cillo, U
    Buda, A
    De Bona, M
    Russo, FP
    Zanus, G
    Cecchetto, A
    D'Amico, DF
    Naccarato, R
    HEPATOLOGY, 1998, 28 (04) : 575A - 575A
  • [46] Treatment of HCV prior to liver transplantation to prevent HCV recurrence - Wise or wasteful?
    Gallegos-Orozco, Juan F.
    Charlton, Michael R.
    LIVER INTERNATIONAL, 2015, 35 (01) : 9 - 11
  • [47] Who should be prioritized for HCV antiviral treatment? A cost-effectiveness analysis including individual and population prevention benefits
    Martin, Natasha K.
    Vickerman, Peter
    Dore, Gregory J.
    Grebely, Jason
    Foster, Graham R.
    Miners, Alec
    Hutchinson, Sharon
    Goldberg, David J.
    Martin, Thomas C.
    HEPATOLOGY, 2014, 60 : 1042A - 1042A
  • [48] Impact of sirolimus on HCV recurrence rates after liver transplantation
    Asthana, Sonal
    Toso, Christian
    Meeberg, Glenda
    Kawahara, Toshiyasu
    Bigam, David
    Shapiro, A. J.
    Mason, Andrew
    Kneteman, Norman
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 306 - 306
  • [49] Predictive factors of HCV recurrence after liver transplantation (OLTx)
    Pevere, S
    Boninsegna, S
    Martines, D
    Cillo, U
    Burra, P
    Boccagni, P
    Zanus, G
    D'Amico, DF
    Naccarato, R
    Fagiuoli, S
    GASTROENTEROLOGY, 2003, 124 (04) : A731 - A731
  • [50] Current management and perspectives for HCV recurrence after liver transplantation
    Coilly, Audrey
    Roche, Bruno
    Samuel, Didier
    LIVER INTERNATIONAL, 2013, 33 : 56 - 62
12345